CO4950559A1 - Derivados de eritromicina - Google Patents
Derivados de eritromicinaInfo
- Publication number
- CO4950559A1 CO4950559A1 CO97055290A CO97055290A CO4950559A1 CO 4950559 A1 CO4950559 A1 CO 4950559A1 CO 97055290 A CO97055290 A CO 97055290A CO 97055290 A CO97055290 A CO 97055290A CO 4950559 A1 CO4950559 A1 CO 4950559A1
- Authority
- CO
- Colombia
- Prior art keywords
- group
- erythromycin
- acceptable salt
- pharmaceutically acceptable
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Un derivado de eritromicina A caracterizado por la fórmula:(en la cual R1 es un grupo representado por la fórmula -OCOCH2 Y (en donde Y es un grupo piridilo, un grupo quinolilo, un grupo p-nitrofenilo, o un grupo representado por la fórmula: -NR4 R5 (en donde R4 y R5 iguales o diferentes, pueden ser un átomo de hidrógeno, un grupo metilo, un grupo piridilmetilo, o un grupo quinolilmetilo o un grupo benciloxicarbonilo)) o un grupo cladinosiloxi, R2 es un átomo de hidrógeno, o R1 y R2 juntos conforman un grupo oxo, R3 es un átomo de hidrógeno, un grupo acetilo, un grupo etil-succinilo o un grupo niconinoilo) o una sal farmacéuticamente aceptable del mismo.Una composición farmacéutica caracterizada por comprender una cantidad efectiva del derivado de eritromicina A o de su sal farmacéuticamente aceptable conforme a la Reivindicación 1.Una preparación bactericida caracterizada por comprender el derivado de eritromicina A o su sal farmacéuticamente aceptable conforme a la reivindicación 1 como un componente efectivo.Un método de tratamiento de una enfermedad infecciosa de origen bacteriano caracterizado por comprender la administración a un paciente de una cantidad farmacéuticamente efectiva del derivado de eritromicina A o de su sal farmacéuticamente aceptable conforme a la Reivindicación 1.El uso del derivado de eritromicina A o de su sal farmacéuticamente aceptable conforme a la Reivindicación 1, caracterizado por tener por objeto el tratamiento de una enfermedad infecciosa de origen bacteriano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25105096 | 1996-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4950559A1 true CO4950559A1 (es) | 2000-09-01 |
Family
ID=17216881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97055290A CO4950559A1 (es) | 1996-09-24 | 1997-09-23 | Derivados de eritromicina |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5804565A (es) |
| JP (1) | JP2001500895A (es) |
| AR (1) | AR008474A1 (es) |
| AU (1) | AU4222797A (es) |
| CO (1) | CO4950559A1 (es) |
| WO (1) | WO1998013373A1 (es) |
| ZA (1) | ZA978546B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1045523A1 (zh) | 1999-05-24 | 2002-11-29 | 辉瑞产品公司 | 13-甲基红霉素衍生物 |
| US20020115621A1 (en) * | 2000-08-07 | 2002-08-22 | Wei-Gu Su | Macrolide antibiotics |
| WO2004101592A1 (ja) * | 2003-05-19 | 2004-11-25 | Taisho Pharmaceutical Co., Ltd. | エリスロマイシンａ誘導体の製造方法 |
| DK1836211T3 (da) | 2004-12-21 | 2010-05-17 | Pfizer Prod Inc | Makrolider |
| AR085286A1 (es) * | 2011-02-21 | 2013-09-18 | Taisho Pharmaceutical Co Ltd | Derivado de macrolido sustituido en la posicion c-4 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331803A (en) * | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
| JPH0633312B2 (ja) * | 1986-05-02 | 1994-05-02 | 大正製薬株式会社 | １４−ハイドロキシエリスロマイシン誘導体およびその製造方法 |
| KR960000434B1 (ko) * | 1986-12-17 | 1996-01-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 에리스로마이신 a유도체 및 그의 제조 방법 |
| IL114589A (en) * | 1990-11-21 | 1999-12-22 | Roussel Uclaf | Intermediates for the preparation of erythromycin derivatives |
| ES2104889T3 (es) * | 1990-11-28 | 1997-10-16 | Taisho Pharmaceutical Co Ltd | Derivado de 6-o-metileritromicina a. |
| US5523399A (en) * | 1991-12-27 | 1996-06-04 | Taisho Pharmaceutical Co., Ltd. | 5-O-desosaminylerythronolide derivatives |
| FR2692579B1 (fr) * | 1992-06-19 | 1995-06-02 | Roussel Uclaf | Nouveaux dérivés de la picromycine, leur procédé de préparation et leur application comme médicaments. |
| US5393743A (en) * | 1993-07-06 | 1995-02-28 | Abbott Laboratories | Erythromycin derivatives |
-
1997
- 1997-09-17 US US08/931,949 patent/US5804565A/en not_active Expired - Fee Related
- 1997-09-22 AU AU42227/97A patent/AU4222797A/en not_active Abandoned
- 1997-09-22 WO PCT/JP1997/003360 patent/WO1998013373A1/en not_active Ceased
- 1997-09-22 AR ARP970104338A patent/AR008474A1/es unknown
- 1997-09-22 JP JP10515485A patent/JP2001500895A/ja active Pending
- 1997-09-23 ZA ZA9708546A patent/ZA978546B/xx unknown
- 1997-09-23 CO CO97055290A patent/CO4950559A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA978546B (en) | 1998-04-01 |
| JP2001500895A (ja) | 2001-01-23 |
| WO1998013373A1 (en) | 1998-04-02 |
| AR008474A1 (es) | 2000-01-19 |
| US5804565A (en) | 1998-09-08 |
| AU4222797A (en) | 1998-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| EA199901014A1 (ru) | C-4"-замещенные макролидные производные | |
| IL173397A0 (en) | Pyridyl derivatives and their use as therapeutic agents | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| EA201000643A1 (ru) | Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе | |
| PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
| EA200300354A1 (ru) | Хинолиноновые производные в качестве ингибиторов тирозинкиназы | |
| ATE269846T1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| MA28008A1 (fr) | Derives pyridyle et leur utilisation en tant qu'agents therapeutiques | |
| BR0110023A (pt) | Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite | |
| BRPI0415373A (pt) | ácidos carboxìlicos macrocìclicos e acilsulfonamidas como inibidores de replicação de hcv | |
| BR0110420A (pt) | Agonistas muscarìnicos | |
| ATE284861T1 (de) | N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden | |
| NZ504986A (en) | Erythromycin and azalide derivatives and pharmaceutical compositions thereof, useful as antibacterial agents and antoprotozoa agents | |
| MX2007000028A (es) | Derivados de nicotinamida y su uso como agentes terapeuticos. | |
| BR9708706B8 (pt) | composição farmacêutica para administração intravenosa a um paciente | |
| EP0992509A3 (en) | Novel macrolide derivatives | |
| NZ510811A (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| WO2007046867A3 (en) | Piperidine derivatives and their uses as therapeutic agents | |
| DE60137146D1 (de) | Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| ATE344249T1 (de) | Pyrazinone, diese verbindungen enthaltende zusammenstellungen | |
| CO4950559A1 (es) | Derivados de eritromicina | |
| KR940702726A (ko) | 치환된 퀴놀린-3-카르복시아미드 화합물의 용도 및 이를 이용한 다발성 경화증의 치료방법 |